BioXcel Therapeutics Enters Material Definitive Agreement
Ticker: BTAI · Form: 8-K · Filed: Apr 3, 2025 · CIK: 1720893
Sentiment: neutral
Topics: material-agreement, filing
TL;DR
BioXcel Therapeutics just signed a big deal, filing an 8-K on April 3, 2025.
AI Summary
BioXcel Therapeutics, Inc. announced on April 3, 2025, that it has entered into a material definitive agreement. The company, incorporated in Delaware with its principal executive offices at 555 Long Wharf Drive, New Haven, CT, is involved in the pharmaceutical preparations industry.
Why It Matters
This filing indicates a significant new contract or partnership for BioXcel Therapeutics, which could impact its future operations and financial performance.
Risk Assessment
Risk Level: medium — Entering into a material definitive agreement can carry inherent risks related to the terms, execution, and potential impact on the company's strategic direction.
Key Players & Entities
- BioXcel Therapeutics, Inc. (company) — Registrant
- April 3, 2025 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of incorporation
- 555 Long Wharf Drive, New Haven, CT (address) — Principal executive offices
FAQ
What is the nature of the material definitive agreement entered into by BioXcel Therapeutics?
The filing does not specify the details of the material definitive agreement, only that one has been entered into on or before April 3, 2025.
When was the material definitive agreement reported?
The report date and the date of the earliest event reported is April 3, 2025.
Where are BioXcel Therapeutics' principal executive offices located?
BioXcel Therapeutics' principal executive offices are located at 555 Long Wharf Drive, New Haven, CT.
What is BioXcel Therapeutics' standard industrial classification?
BioXcel Therapeutics' standard industrial classification is Pharmaceutical Preparations [2834].
What is the company's state of incorporation?
The company is incorporated in Delaware.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on April 3, 2025 regarding BioXcel Therapeutics, Inc. (BTAI).